Tautomycin suppresses growth and neuroendocrine hormone markers in carcinoid cells through activation of the Raf-1 pathway
Scott N. Pinchot, Joel T. Adler, Yinggang Luo, Jianhua Ju, Wenli Li, Ben Shen, Muthusamy Kunnimalaiyaan, Herbert Chen
Index: Am. J. Surg. 197(3) , 313-9, (2009)
Full Text: HTML
Abstract
Background Carcinoids are neuroendocrine (NE) tumors with limited treatment options. Raf-1 pathway activation has been shown to suppress hormone production in carcinoid cells. We investigated a novel treatment for carcinoid cell growth based on pharmacologic Raf-1 activation using the compound tautomycin (TTY).
Related Compounds
Related Articles:
2009-03-27
[J. Nat. Prod. 72(3) , 450-9, (2009)]
2006-08-16
[J. Am. Chem. Soc. 128(32) , 10386-7, (2006)]
2009-08-21
[J. Biol. Chem. 284 , 22649 - 22656, (2009)]
Tautomycin's interactions with protein phosphatase 1.
2010-03-01
[Chem. Asian J. 5(3) , 410-20, (2010)]
2009-04-02
[Org. Lett. 11(7) , 1639-42, (2009)]